For anyone who attended the Zenith AGM was there any discussion of share liquidity either in the presentation or during the Q & A?

My sense is that Zenith Epigenetics is only at the earlist stages of clinical trials. From what I have seen on these companies they tend to not have very high valuations. However, there are always exceptions.

Any thoughts or info?

Thanks

Toinv